Breaking News
Get 40% Off 0
🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought it Read More
Close

Enzychem Lifesciences Corp (183490)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1,914 +17    +0.90%
20:08:40 - Delayed Data. Currency in KRW ( Disclaimer )
Type:  Equity
Market:  South Korea
ISIN:  KR7183490002 
  • Volume: 13,002
  • Bid/Ask: 1,897 / 1,914
  • Day's Range: 1,884 - 1,914
Enzychem Lifesciences 1,914 +17 +0.90%

183490 Balance Sheet

 
Featured here, the Balance Sheet for Enzychem Lifesciences Corp, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
Advanced Balance Sheet
Period Ending: 2024
31/03
2023
31/12
2023
30/09
2023
30/06
Total Current Assets 172796.19 174475.03 179355.52 177567.61
Cash and Short Term Investments 127267.36 137350.22 145356.43 151687.09
Cash - - - -
Cash & Equivalents 18352.34 15470.22 4672.84 8102.84
Short Term Investments 108639.01 121604 125598.12 143584.25
Total Receivables, Net 27922.81 20207.42 17425.41 10565.9
Accounts Receivables - Trade, Net 12492.56 11625.32 13022.77 8486.14
Total Inventory 15345.16 14945.87 14401.14 13771.19
Prepaid Expenses 141.66 134.77 173.27 149.94
Other Current Assets, Total 2119.2 1836.75 1999.26 1393.5
Total Assets 208400.02 211545.51 216222.31 214371.85
Property/Plant/Equipment, Total - Net 25496.3 26164.19 26190.05 26017.79
Property/Plant/Equipment, Total - Gross 41426.56 41363.02 41055.2 40214.06
Accumulated Depreciation, Total -15930.26 -15198.83 -14865.15 -14196.28
Goodwill, Net 1479.5 1479.5 1394.5 1394.5
Intangibles, Net 4010.36 4371.45 4571.58 4723.58
Long Term Investments 1257.79 1573.97 870.23 814.41
Note Receivable - Long Term 1018.52 1425.35 860.3 1171.39
Other Long Term Assets, Total 2744.31 2859.43 3398.28 3405.54
Other Assets, Total 113483.87 126233.88 143643.06 149539.83
Total Current Liabilities 12021.31 14154.1 15330.42 11067.43
Accounts Payable 5249.4 6493.2 6998.48 2940.54
Payable/Accrued - - - -
Accrued Expenses 8.81 10.21 39.25 40.13
Notes Payable/Short Term Debt 2160 2280 2553.82 2000
Current Port. of LT Debt/Capital Leases 1384.94 1767.51 1865.47 2602.48
Other Current liabilities, Total 3218.17 3603.18 3873.41 3484.28
Total Liabilities 14836.13 16918.87 20801.47 16214.28
Total Long Term Debt 1534.1 1609.45 1674.4 1579.57
Long Term Debt 1017.5 1025 1032.5 1040
Capital Lease Obligations 516.6 584.45 641.9 539.57
Deferred Income Tax 703.37 715.09 735.28 753.03
Minority Interest 1117.1 1110.71 1092.82 1202.16
Other Liabilities, Total -2699.75 -2950.48 -585.28 -387.89
Total Equity 193563.89 194626.64 195420.84 198157.57
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 42532.78 42532.78 42532.78 42532.78
Additional Paid-In Capital 108956.66 108431.48 108431.48 108431.48
Retained Earnings (Accumulated Deficit) 40821.38 41910.07 42705.15 45339.73
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 1253.07 1752.3 1751.42 1853.57
Total Liabilities & Shareholders' Equity 208400.02 211545.51 216222.31 214371.85
Total Common Shares Outstanding 85.07 85.07 85.07 85.07
Total Preferred Shares Outstanding - - - -
* In Millions of KRW (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

183490 Comments

Write your thoughts about Enzychem Lifesciences Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email